• Engineered Esophagus Shows Functional Integration in Minipig

  2026-09-21

  The reference study combines an autologous cell-seeded decellularized scaffold with bioreactor conditioning, temporary intraluminal support, and vascularizing pleural coverage to repair circumferential esophageal defects in growing minipigs. The resulting grafts showed progressive structural, vascular, neuromuscular, and functional maturation, including secondary peristalsis and oral feeding, although survival and long-term translation remain important constraints.

• Resazurin sodium salt: Reliable Viability Assays

  2026-09-21

  This scenario-based guide explains how Resazurin sodium salt, SKU B6098, can improve the interpretation and reproducibility of fluorescence-based cell viability, proliferation, and cytotoxicity assays. It covers redox principles, solvent compatibility, workflow controls, metabolic confounding, and practical supplier-selection criteria.

• Oligo (dT) 25 Beads for Immune-Cell RNA Assays

  2026-09-20

  Oligo (dT) 25 Beads provide selective polyA tail mRNA capture for rigorous eukaryotic immune-cell RNA workflows. This guide explains how their use can support, but should not be confused with, single-cell studies of immune rejuvenation in Alzheimer’s disease models.

• LNP-mRNA Fibroblasts for Intervertebral Disc Repair

  2026-09-19

  The reference study develops fibroblasts engineered with lipid nanoparticle-delivered mRNA encoding a TNF-α-neutralizing antibody, combining cell-based delivery with local cytokine modulation. In inflammatory cell experiments and a rat intervertebral disc degeneration model, the engineered cells protected fibroblast function, improved extracellular matrix-related outcomes, and produced greater disc-height preservation than unmodified fibroblasts.

• PF-573228: FAK Inhibitor Evidence & Workflow

  2026-09-18

  PF-573228 is an ATP-competitive FAK inhibitor with a reported biochemical IC50 of 4 nM. Evidence supports its use for dissecting FAK phosphorylation, cancer cell migration, endothelial responses, and FAK/MAPK/ERK signaling in experimental models.

• Tin Mesoporphyrin IX: HO Inhibition Guide

  2026-09-18

  Tin Mesoporphyrin IX (chloride) is a competitive heme oxygenase inhibitor with a reported in vitro Ki of 14 nM against rat splenic microsomal heme oxygenase. Its strongest research value is as a mechanistic tool for heme catabolism, metabolic disease research, and carefully controlled HO-linked redox studies rather than as a clinical or established antiviral treatment.

• RapaLink-1: Designing Better mTOR Assays

  2026-09-17

  RapaLink-1 is a third-generation mTOR inhibitor that enables more discriminating studies of mTORC1 inhibition, resistant signaling, and phenotype. This article develops an assay-design framework linking its bivalent pharmacology to insights from reversible embryonic dormancy models.

• Caged Bioluminescent Probe for Immunoproteasome

  2026-09-17

  Loy and Trader describe a cleavable, bioluminescent activity-based probe designed to report immunoproteasome activity, with emphasis on the β5i-containing isoform. The synthesis and plate-reader workflow offers a practical route for studying immunoproteasome function in cellular systems and tissue-mimicking conditions, while the authors identify in vivo translation as an important next step.

• NBC19: Linking Inflammasome Assays to CAML Biology

  2026-09-16

  NBC19, a potent NLRP3 inflammasome inhibitor, offers a precise way to test how inflammatory signaling may intersect with circulating cancer-associated macrophage-like cells. This article translates CAML phenotyping insights into better assay design while clearly separating established evidence from testable hypotheses.

• Tyrothricin: Applied Antimicrobial Workflows

  2026-09-16

  Tyrothricin is a peptide antibiotic mixture suited to rapid, mechanism-focused studies of microbial membrane injury across bacteria and selected nonbacterial models. This guide translates the product’s membrane-disruption profile and a redox-biology reference study into practical assay design, controls, and troubleshooting steps.

• ER-Targeting Peptide Self-Assembly in Cancer Cells

  2026-09-15

  The reference study develops an alkaline-phosphatase-triggered peptide that self-assembles at the endoplasmic reticulum through a p-toluenesulfonamide targeting group. This design selectively increases ER stress and cancer-cell death while reducing the concentration dependence of earlier intracellular enzyme-instructed self-assembly strategies.

• CGP 55845 Hydrochloride in GABAB Assays

  2026-09-14

  Use CGP 55845 hydrochloride as a receptor-level control when separating GABAB signaling from astrocytic GAT-3 effects in dentate gyrus experiments. This practical guide connects antagonist pharmacology with whole-cell recording, calcium imaging, optogenetics, and neurotransmitter release modulation while emphasizing in vitro interpretation limits.

• Moxifloxacin: From Gyrase Traps to Toxicity Models

  2026-09-14

  Moxifloxacin is a fluoroquinolone antibiotic that connects bacterial DNA-gyrase pharmacology with cellular and metabolic toxicity research. This guide presents a target-engagement framework for selecting assays, interpreting retinal-cell findings, and controlling compound handling.

• Dehydroepiandrosterone (DHEA) Research Workflows

  2026-09-13

  Dehydroepiandrosterone (DHEA) supports two distinct research strategies: endocrine challenge modeling in ovarian biology and concentration-controlled studies of neural survival. This practical guide connects formulation, assay design, and troubleshooting with the mitochondrial steroidogenesis findings reported in a recent PCOS study.

• Prednisone as a Translational Immunology Benchmark

  2026-09-12

  Prednisone offers translational researchers a defined synthetic corticosteroid benchmark for studying lymphocyte cell-cycle control, IL-2 signaling, apoptosis, formulation variables, and the limits of connecting immune assays with neurodegeneration models.

8539 records 1/570 page Next 12345 下5页 Last page